Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Anticancer Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025

Table of Content

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Anticancer Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Drug Type Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunity
            4.3.4. Trends
     4.4. Global Anticancer Drugs Market Analysis and Forecasts, 2015-2025
            4.4.1. Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis
     4.6. Value Chain Analysis
     4.7. Market Outlook
     4.8. Pipeline Analysis
     4.9. Disease Overview
     4.10. Evolution of Cancer Therapies

5. Global Anticancer Drugs Market Analysis and Forecasts, By Drug Type 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Market Value Forecast By Drug Type , 2015-2025
            5.3.1. Cytotoxic Drugs
                     5.3.1.1. Alkylating Agents
                     5.3.1.2. Antimetabolites
                     5.3.1.3. Others
            5.3.2. Targeted Drugs
                     5.3.2.1. Monoclonal Antibodies
                     5.3.2.2. Tyrosine Kinase Inhibitors
                     5.3.2.3. Others
            5.3.3. Hormonal Drugs
     5.4. Market Attractiveness By Drug Type 

6. Global Anticancer Drugs Market Analysis and Forecasts, By Therapy Type 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Value Forecast By Therapy Type , 2015-2025
            6.3.1. Chemotherapy
            6.3.2. Targeted Therapy
            6.3.3. Immunotherapy
            6.3.4. Others
     6.4. Market Attractiveness By Therapy Type 

7. Global Anticancer Drugs Market Analysis and Forecasts, By Cancer Type 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Value Forecast By Cancer Type , 2015-2025
            7.3.1. Lung Cancer
            7.3.2. Breast Cancer
            7.3.3. Leukemia
            7.3.4. Colorectal Cancer
            7.3.5. Others
     7.4. Market Attractiveness By Cancer Type 

8. Global Anticancer Drugs Market Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Market Value Forecast By Region
            8.2.1. North America 
            8.2.2. Europe 
            8.2.3. Asia Pacific 
            8.2.4. Latin America 
            8.2.5. Middle East & Africa 
     8.3. Market Attractiveness By Region

9. North America Anticancer Drugs Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Key Trends
     9.2. Market Value Forecast By Drug Type , 2015-2025
            9.2.1. Cytotoxic Drugs
                     9.2.1.1. Alkylating Agents
                     9.2.1.2. Antimetabolites
                     9.2.1.3. Others
            9.2.2. Targeted Drugs
                     9.2.2.1. Monoclonal Antibodies
                     9.2.2.2. Tyrosine Kinase Inhibitors
                     9.2.2.3. Others
            9.2.3. Hormonal Drugs
     9.3. Market Value Forecast By Therapy Type , 2015-2025
            9.3.1. Chemotherapy
            9.3.2. Targeted Therapy
            9.3.3. Immunotherapy
            9.3.4. Others
     9.4. Market Value Forecast By Cancer Type , 2015-2025
            9.4.1. Lung Cancer
            9.4.2. Breast Cancer
            9.4.3. Leukemia
            9.4.4. Colorectal Cancer
            9.4.5. Others
     9.5. Market Value Forecast By Country, 2015-2025
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis 
            9.6.1. By Drug Type 
            9.6.2. By Therapy Type 
            9.6.3. By Cancer Type 
            9.6.4. By Country

10. Europe Anticancer Drugs Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
            10.1.2. Key Trends
     10.2. Market Value Forecast By Drug Type , 2015-2025
            10.2.1. Cytotoxic Drugs
                     10.2.1.1. Alkylating Agents
                     10.2.1.2. Antimetabolites
                     10.2.1.3. Others
            10.2.2. Targeted Drugs
                     10.2.2.1. Monoclonal Antibodies
                     10.2.2.2. Tyrosine Kinase Inhibitors
                     10.2.2.3. Others
            10.2.3. Hormonal Drugs
     10.3. Market Value Forecast By Therapy Type , 2015-2025
            10.3.1. Chemotherapy
            10.3.2. Targeted Therapy
            10.3.3. Immunotherapy
            10.3.4. Others
     10.4. Market Value Forecast By Cancer Type , 2015-2025
            10.4.1. Lung Cancer
            10.4.2. Breast Cancer
            10.4.3. Leukemia
            10.4.4. Colorectal Cancer
            10.4.5. Others
     10.5. Market Value Forecast By Country / Sub-region, 2015-2025
            10.5.1. U.K. 
            10.5.2. Germany
            10.5.3. France
            10.5.4. Italy 
            10.5.5. Spain 
            10.5.6. Rest of Europe
     10.6. Market Attractiveness Analysis 
            10.6.1. By Drug Type 
            10.6.2. By Therapy Type 
            10.6.3. By Cancer Type 
            10.6.4. By Country / Sub-region

11. Asia Pacific Anticancer Drugs Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
            11.1.2. Key Trends
     11.2. Market Value Forecast By Drug Type , 2015-2025
            11.2.1. Cytotoxic Drugs
                     11.2.1.1. Alkylating Agents
                     11.2.1.2. Antimetabolites
                     11.2.1.3. Others
            11.2.2. Targeted Drugs
                     11.2.2.1. Monoclonal Antibodies
                     11.2.2.2. Tyrosine Kinase Inhibitors
                     11.2.2.3. Others
            11.2.3. Hormonal Drugs
     11.3. Market Value Forecast By Therapy Type , 2015-2025
            11.3.1. Chemotherapy
            11.3.2. Targeted Therapy
            11.3.3. Immunotherapy
            11.3.4. Others
     11.4. Market Value Forecast By Cancer Type , 2015-2025
            11.4.1. Lung Cancer
            11.4.2. Breast Cancer
            11.4.3. Leukemia
            11.4.4. Colorectal Cancer
            11.4.5. Others
     11.5. Market Value Forecast By Country / Sub-region, 2015-2025
            11.5.1. China
            11.5.2. Japan
            11.5.3. India
            11.5.4. Australia & New Zealand
            11.5.5. Rest of Asia Pacific
     11.6. Market Attractiveness Analysis 
            11.6.1. By Drug Type 
            11.6.2. By Therapy Type 
            11.6.3. By Cancer Type 
            11.6.4. By Country / Sub-region

12. Latin America Anticancer Drugs Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
            12.1.2. Key Trends
     12.2. Market Value Forecast By Drug Type , 2015-2025
            12.2.1. Cytotoxic Drugs
                     12.2.1.1. Alkylating Agents
                     12.2.1.2. Antimetabolites
                     12.2.1.3. Others
            12.2.2. Targeted Drugs
                     12.2.2.1. Monoclonal Antibodies
                     12.2.2.2. Tyrosine Kinase Inhibitors
                     12.2.2.3. Others
            12.2.3. Hormonal Drugs
     12.3. Market Value Forecast By Therapy Type , 2015-2025
            12.3.1. Chemotherapy
            12.3.2. Targeted Therapy
            12.3.3. Immunotherapy
            12.3.4. Others
     12.4. Market Value Forecast By Cancer Type , 2015-2025
            12.4.1. Lung Cancer
            12.4.2. Breast Cancer
            12.4.3. Leukemia
            12.4.4. Colorectal Cancer
            12.4.5. Others
     12.5. Market Value Forecast By Country / Sub-region, 2015-2025
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6. Market Attractiveness Analysis 
            12.6.1. By Drug Type 
            12.6.2. By Therapy Type 
            12.6.3. By Cancer Type 
            12.6.4. By Country / Sub-region

13. Middle East & Africa Anticancer Drugs Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
            13.1.2. Key Trends
     13.2. Market Value Forecast By Drug Type , 2015-2025
            13.2.1. Cytotoxic Drugs
                     13.2.1.1. Alkylating Agents
                     13.2.1.2. Antimetabolites
                     13.2.1.3. Others
            13.2.2. Targeted Drugs
                     13.2.2.1. Monoclonal Antibodies
                     13.2.2.2. Tyrosine Kinase Inhibitors
                     13.2.2.3. Others
            13.2.3. Hormonal Drugs
     13.3. Market Value Forecast By Therapy Type , 2015-2025
            13.3.1. Chemotherapy
            13.3.2. Targeted Therapy
            13.3.3. Immunotherapy
            13.3.4. Others
     13.4. Market Value Forecast By Cancer Type , 2015-2025
            13.4.1. Lung Cancer
            13.4.2. Breast Cancer
            13.4.3. Leukemia
            13.4.4. Colorectal Cancer
            13.4.5. Others
     13.5. Market Value Forecast By Country / Sub-region, 2015-2025
            13.5.1. GCC Countries
            13.5.2. South Africa
            13.5.3. Rest of MEA
     13.6. Market Attractiveness Analysis 
            13.6.1. By Drug Type 
            13.6.2. By Therapy Type 
            13.6.3. By Cancer Type 
            13.6.4. By Country / Sub-region

14. Competition Landscape
     14.1. Market Player – Competition Matrix (By Tier and Size of companies)
     14.2. Market Share Analysis By Company (2016)
     14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. F. Hoffmann-La Roche Ltd
                     14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.1.2. Product Portfolio
                     14.3.1.3. SWOT Analysis
                     14.3.1.4. Financial Overview
                     14.3.1.5. Strategic Overview
            14.3.2. Eli Lilly and Company
                     14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.2.2. Product Portfolio
                     14.3.2.3. SWOT Analysis
                     14.3.2.4. Financial Overview
                     14.3.2.5. Strategic Overview
            14.3.3. Novartis AG
                     14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.3.2. Product Portfolio
                     14.3.3.3. SWOT Analysis
                     14.3.3.4. Financial Overview
                     14.3.3.5. Strategic Overview
            14.3.4. Pfizer Inc
                     14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.4.2. Product Portfolio
                     14.3.4.3. SWOT Analysis
                     14.3.4.4. Financial Overview
                     14.3.4.5. Strategic Overview
            14.3.5. Bayer AG
                     14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.5.2. Product Portfolio
                     14.3.5.3. SWOT Analysis
                     14.3.5.4. Financial Overview
                     14.3.5.5. Strategic Overview
            14.3.6. AstraZeneca
                     14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.6.2. Product Portfolio
                     14.3.6.3. SWOT Analysis
                     14.3.6.4. Financial Overview
                     14.3.1.5. Strategic Overview
            14.3.7. Takeda Pharmaceutical Company Limited
                     14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.7.2. Product Portfolio
                     14.3.7.3. SWOT Analysis
                     14.3.7.4. Financial Overview
                     14.3.7.5. Strategic Overview
            14.3.8. Merck & Co., Inc.
                     14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.8.2. Product Portfolio
                     14.3.8.3. SWOT Analysis
                     14.3.8.4. Financial Overview
                     14.3.8.5. Strategic Overview
            14.3.9. CELGENE CORPORATION
                     14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.9.2. Product Portfolio
                     14.3.9.3. SWOT Analysis
                     14.3.9.4. Financial Overview
                     14.3.9.5. Strategic Overview
            14.3.10. Amgen Inc
                     14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.10.2. Product Portfolio
                     14.3.10.3. SWOT Analysis
                     14.3.10.4. Financial Overview
                     14.3.10.5. Strategic Overview

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote